Document is current
Any future updates will be listed below
-
Authors
Powell, Reid T. https://orcid.org/0000-0002-6242-8315
Rinkenbaugh, Amanda L. https://orcid.org/0000-0003-3276-6863
Guo, Lei
Cai, Shirong
Shao, Jiansu
Zhou, Xinhui
Zhang, Xiaomei https://orcid.org/0000-0003-0964-8922
Jeter-Jones, Sabrina
Fu, Chunxiao
Qi, Yuan https://orcid.org/0000-0001-9718-7593
Baameur Hancock, Faiza
White, Jason B.
Stephan, Clifford https://orcid.org/0000-0003-0657-6484
Davies, Peter J. https://orcid.org/0000-0003-0770-2796
Moulder, Stacy
Symmans, W. Fraser https://orcid.org/0000-0002-1526-184X
Chang, Jeffrey T. https://orcid.org/0000-0002-4578-5636
Piwnica-Worms, Helen https://orcid.org/0000-0003-4210-6738
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP150148, RP160710, RP200668, RP160710, RP160710)
- License Information
-
More Information
Article History
Received: 16 August 2023
Accepted: 9 May 2024
First Online: 27 May 2024
Competing interests
: S.L.M. is an employee of and holds stock in Eli Lilly. W.F.S. owns founder stock in Delphi Diagnostics and publicly traded stock in IONIS Pharmaceuticals and Eiger BioPharmaceuticals; is a consultant/advisor to Merck, Astra Zeneca; W.F.S. and C.F. are co-inventors of “Targeted Measure of Transcriptional Activity Related to Hormone Receptors”, United States, Patent No. 11,459,617; has received support for unrelated research from Pfizer; has nothing to disclose for travel, accommodations, expenses; and is an uncompensated scientific advisor to Delphi Diagnostics. All other authors have no competing financial or non-financial interests.
